Keith Syson Chan
- Oncology top 1%
- Cytokine Signaling Pathways and Interactions 10
- Cancer Immunotherapy and Biomarkers 7
- Cancer Cells and Metastasis 6
- Immunology top 2%
- Immunotherapy and Immune Responses 5
- Cancer Research top 2%
- Dermatology top 1%
- Molecular Biology top 5%
- Epigenetics and DNA Methylation 10
- PI3K/AKT/mTOR signaling in cancer 8
-
- Bladder and Urothelial Cancer Treatments 14
- Urinary and Genital Oncology Studies 7
- Co-authors
- John DiGiovanniShigetoshi SanoKaoru KiguchiPhilip Levy HoSteve CarbajalAntonina V. KurtovaJohn L. CliffordQianxing Mo
- Cited by
- OncologyImmunologyCancer Research
- Journals
- Nature Communications (7 papers)Cancer Research (5 papers)Proceedings of the National Academy of Sciences (3 papers)
- Partner nations
- United StatesTaiwanJapan
In The Last Decade
Keith Syson Chan
50 papers receiving 4.7k citations
Hit Papers
Peers
Comparison fields: 5 of 121
- Oncology 2.0k
- Immunology 1.3k
- Cancer Research 848
- Dermatology 379
- Molecular Biology 2.2k
Countries citing papers authored by Keith Syson Chan
This map shows the geographic impact of Keith Syson Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Syson Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Syson Chan more than expected).
Fields of papers citing papers by Keith Syson Chan
This network shows the impact of papers produced by Keith Syson Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Syson Chan. The network helps show where Keith Syson Chan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Keith Syson Chan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 4 | |
| 2 | 2025 | 3 | |
| 3 | 2024 | 11 | |
| 4 | Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomasbreakdown → | 2024 | 52 |
| 5 | 2022 | 5 | |
| 6 | 2021 | 23 | |
| 7 | 2021 | 103 | |
| 8 | 2020 | 10 | |
| 9 | 2020 | 212 | |
| 10 | 2019 | 34 | |
| 11 | 2017 | 13 | |
| 12 | Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistancebreakdown → | 2014 | 451 |
| 13 | 2012 | 111 | |
| 14 | 2012 | 187 | |
| 15 | 2012 | 142 | |
| 16 | 2008 | 27 | |
| 17 | 2007 | 89 | |
| 18 | 2004 | 271 | |
| 19 | Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. | 2001 | 142 |
| 20 | 1981 | 2 |
About Keith Syson Chan
Keith Syson Chan is a scholar working on Oncology, Cancer Research and Immunology, having authored 53 papers that have together received 4.7k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (14 papers), Epigenetics and DNA Methylation (10 papers), Cytokine Signaling Pathways and Interactions (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Urinary and Genital Oncology Studies (7 papers), Cancer Cells and Metastasis (6 papers) and Immunotherapy and Immune Responses (5 papers). The work is most often cited by research in Oncology (2.0k citations), Immunology (1.3k citations) and Cancer Research (848 citations). Keith Syson Chan has collaborated with scholars based in United States, Taiwan and Japan. Frequent co-authors include John DiGiovanni, Shigetoshi Sano, Kaoru Kiguchi, Philip Levy Ho, Steve Carbajal, Antonina V. Kurtova, John L. Clifford, Qianxing Mo, Junji Takeda and Irving L. Weissman. Their work appears in journals such as Nature Communications, Cancer Research, Proceedings of the National Academy of Sciences, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.